Table 2.
Factors related to the performance of prostate-specific antigen testing in a cohort of French men older than 74 years (mixed-effects multivariate logistic regression with general practitioner as a random effect).
| Characteristics | Proportion of patients screened using PSAa,b (%) | Crude odds ratio (95% CI)c | P valued | Adjusted odds ratio (95% CI)e | P valuef | ||
| Age in years | N/Ag | 0.89 (0.89-0.90) | <.001 | 0.89 (0.88-0.89) | <.001 | ||
| Low socioeconomic statush | 13.04 | 0.25 (0.07-0.89) | .03 | 0.18 (0.05-0.69) | .01 | ||
| Frail individual | |||||||
|
|
Chronic disease status | 39.61 | 0.80 (0.75-0.85) | <.001 | 0.82 (0.76-0.88) | <.001 | |
|
|
Repeated ambulance transportation | 18.77 | 0.28 (0.22-0.36) | <.001 | 0.42 (0.33-0.54) | <.001 | |
|
|
Chronic treatment with ≥5 drugs | 41.50 | 0.98 (0.92-1.05) | .57 | N/A | N/A | |
| Cancer disease (treated with anticancer drug) | 39.62 | 0.88 (0.67-1.16) | .36 | N/A | N/A | ||
| Cardiovascular disease | |||||||
|
|
Number of cardiovascular drugs | ||||||
|
|
|
0 | 35.93 | Reference | N/A | Reference | N/A |
|
|
|
1-2 | 43.53 | 1.44 (1.32-1.57) | <.001 | 1.68 (1.53-1.84) | <.001 |
|
|
|
3-4 | 42.63 | 1.37 (1.25-1.49) | <.001 | 1.73 (1.57-1.91) | <.001 |
|
|
|
5 or more | 40.91 | 1.24 (1.13-1.37) | <.001 | 1.64 (1.46-1.84) | <.001 |
|
|
Treated with insulin | 27.22 | 0.49 (0.42-0.58) | <.001 | 0.62 (0.51-0.75) | <.001 | |
|
|
Treated with antiaggregant | 41.43 | 0.99 (0.93-1.05) | .80 | N/A | N/A | |
| Dementia (treated with anticholinesterase therapy) | 25.83 | 0.44 (0.36-0.54) | <.001 | 0.68 (0.55-0.84) | <.001 | ||
| Psychiatric disorder (treated with antipsychotic therapy) | 29.02 | 0.49 (0.40-0.58) | <.001 | 0.62 (0.51-0.75) | <.001 | ||
| Other variables indicative of comorbidities | N/A | N/A | |||||
|
|
Oxygen at home | 43.30 | 1.12 (0.96-1.29) | .14 |
|
|
|
|
|
>8 urea/creatinine tests during the study period | 43.93 | 1.25 (0.94-1.66) | .12 |
|
|
|
|
|
>4 alpha-fetoprotein tests during the study period | 41.07 | 1.06 (0.58-1.91) | .85 |
|
|
|
aProstate-specific antigen.
bn=22,480.
cGeneral practitioner as a random effect; bivariate analysis.
dP value for crude odds ratio.
eGeneral practitioner as a random effect; multivariate analysis; adjusted on the variable “treatment for benign prostate hyperplasia.”
fP value for adjusted odds ratio.
gN/A: not applicable.
hDefined as an annual income less than 8593 € (US $9992) for an individual or less than 12889 € (US $14,925) for a couple.